Device Trial Radar · NCT04503564
"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
Last checked: Nov 20, 2026Latest source record: Mar 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Nov 13, 2019
Primary completion
Nov 11, 2020
Study completion Nov 11, 2020
Sponsor
- Lead sponsor
- Capillary Biomedical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 7, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Over 1 million patients globally currently manage their Type 1 Diabetes mellitus using continuous subcutaneous insulin infusion with an infusion set that needs to be changed every 3 days. This study will assess the feasibility and device performance of the study device, the Achilles infusion set over three periods during routine insulin infusion. This study will include 20 participants and has 3 periods: Period 1 (up to 7 days): Trial run with study device with saline infusion. Period 2 (up to 7 days): participants will manage their blood glucose solely with their insulin pump and the Achilles infusion set. Blood glucose will be closely monitored with a continuous glucose monitoring (CGM) device. Period 3 (up to 7 days): Participants will return to study center to receive a fresh Achilles infusion set and continue blood glucose management at home until infusion set failure or 7 days.
Conditions
- Diabetes Mellitus, Type 1
- Type 1 Diabetes
- Type 1 Diabetes Mellitus
- Diabetes Mellitus, Insulin-Dependent, 1
Interventions
coil-reinforced soft polymer indwelling cannulaDevice
This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Infusion Set Survival at End of Day 7Time frame: 7 days during weeks 2 and 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.